NKTR
NASDAQ · Pharmaceuticals
Nektar Therapeutics
$67.10
-1.26 (-1.84%)
Financial Highlights (FY 2026)
Revenue
109.53M
Net Income
-325,390,330
Gross Margin
100.0%
Profit Margin
-297.1%
Rev Growth
-15.7%
D/E Ratio
0.70
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 33.1% | 33.1% |
| Operating Margin | -253.7% | -228.3% | 30.6% | 35.1% |
| Profit Margin | -297.1% | -282.2% | 23.0% | 25.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 109.53M | 129.89M | 246.52M | 245.87M |
| Gross Profit | 109.53M | 129.89M | 81.64M | 81.42M |
| Operating Income | -277,844,177 | -296,525,268 | 75.50M | 86.21M |
| Net Income | -325,390,330 | -347,268,228 | 56.66M | 62.08M |
| Gross Margin | 100.0% | 100.0% | 33.1% | 33.1% |
| Operating Margin | -253.7% | -228.3% | 30.6% | 35.1% |
| Profit Margin | -297.1% | -282.2% | 23.0% | 25.3% |
| Rev Growth | -15.7% | -15.7% | +15.2% | +17.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 481.78M | 481.78M | 257.51M | 280.38M |
| Total Equity | 685.23M | 685.23M | 292.45M | 319.03M |
| D/E Ratio | 0.70 | 0.70 | 0.88 | 0.88 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -275,809,241 | -310,706,485 | 106.98M | 112.84M |
| Free Cash Flow | — | — | 45.61M | 47.98M |